Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

Company price
None USD 0.00(0%)
Last update at 2025-07-17T13:08:57.173495Z
Market Cap
1.38M

Momentum Score

…

CRISM Therapeutics Corporation focuses on drug delivery technology to improve the clinical performance of cancer drugs as treatments for solid tumors. Its lead product, ChemoSeed that can be implanted directly into a tumor or the resection margin following the removal of a tumor, ensuring effective therapeutic concentrations of chemotherapy drugs directly reach the tumor tissue. Its ChemoSeed used for treatment of gliomas, a brain tumor. The company was founded in 2016 and is based in Road Town, the British Virgin Islands.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
0.04
Low
0.04
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
-
Dividend Yield
-
Revenue TTM
-0.03M
Revenue Per Share
-0.00
Gross Profit TTM
0.00M
Debt / Equity
-
ROE
-62.67%
Net Debt
-4.38M
ROCE
-63.17%
Diluted EPS TTM
-0.34

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -2.60M -1.79M -2.67M -2.33M -3.31M
Minority interest - - - - 0.00M
Net income -3.01M -1.21M -2.67M -2.33M -3.31M
Selling general administrative 2.60M 1.79M 3.08M 1.98M 2.15M
Gross profit - - - - 0.00M
Ebit - -1.79M -3.08M -1.98M -2.15M
Ebitda -2.60M -1.79M -2.88M -1.98M -2.15M
Depreciation and amortization - - 0.20M 0.00M 0.00M
Non operating income net other - - - - 0.00M
Operating income -2.60M -1.79M -3.08M -1.98M -2.15M
Other operating expenses 2.60M 1.79M 3.08M 1.98M 2.15M
Interest expense - 0.00M 0.10M 0.80M 1.22M
Tax provision 0.00M 0.00M 0.00M 0.00M 0.00M
Interest income - 0.00M 0.20M 0.00M 0.00M
Net interest income - 0.00M 0.10M -0.80M -1.22M
Extraordinary items - - - - 0.00M
Non recurring - - - - 0.00M
Other items - - - - 0.00M
Income tax expense 0.41M -0.58M - - 0.00M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 2.60M 1.79M 3.08M 1.98M 2.15M
Cost of revenue - - - - 0.00M
Total other income expense net - - 0.41M -0.34M -1.16M
Discontinued operations - 0.58M 0.58M 0.58M 0.58M
Net income from continuing ops -2.60M -1.79M -2.67M -2.33M -3.31M
Net income applicable to common shares - -1.21M -2.67M -2.33M -3.31M
Preferred stock and other adjustments - - - - 0.00M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 4.79M 28.74M 31.24M 32.40M 28.75M
Other current assets 0.40M 25.20M 24.45M - -
Total liab 0.66M 0.92M 1.13M 1.05M 1.13M
Total stockholder equity 4.12M 27.82M 30.11M 31.35M 27.62M
Other current liab 0.19M 0.18M 0.16M 0.00M 0.03M
Common stock 80.79M 80.79M 80.45M 80.45M 69.51M
Capital stock 80.79M 80.79M 80.45M 80.45M 69.51M
Retained earnings -80.95M -40.53M -37.52M -36.48M -34.95M
Other liab - - 0.16M 0.14M 0.16M
Cash 4.38M 3.48M 6.68M 2.79M 0.40M
Total current liabilities 0.66M 0.92M 1.13M 0.91M 0.96M
Net debt -4.38M -3.48M -6.68M -2.79M -0.40M
Short long term debt - - - 0.00M 0.00M
Other stockholder equity 4.28M -12.45M -12.82M -12.62M -6.94M
Property plant equipment - - - 0.45M 27.38M
Total current assets 4.79M 28.74M 31.24M 3.15M 0.89M
Net tangible assets - - 30.11M 7.81M 27.14M
Net receivables 0.40M 0.06M 0.11M 0.01M 0.03M
Inventory 0.00M - 0.00M 0.21M 0.28M
Accounts payable 0.47M 0.74M 0.97M 0.91M 0.96M
Accumulated other comprehensive income 0.00M - - - -
Non currrent assets other - - - 5.25M -
Non current assets total 0.00M 0.00M 0.00M 29.25M 27.87M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -0.19M 6.04M -5.18M -0.50M -2.05M
Change to liabilities - 0.00M 0.00M 0.00M 0.00M
Total cashflows from investing activities - 6.04M -5.18M -0.50M -2.05M
Net borrowings - - -0.11M -0.34M 3.45M
Total cash from financing activities 0.34M - 9.89M 1.50M 3.45M
Change to operating activities - - - - 0.00M
Net income -3.01M -1.21M -2.67M -2.33M -3.31M
Change in cash -3.20M 3.89M 2.39M -0.86M -1.30M
Begin period cash flow 6.68M 2.79M 0.40M 1.26M 2.56M
End period cash flow 3.48M 6.68M 2.79M 0.40M 1.26M
Total cash from operating activities - -1.83M -2.20M -1.90M -2.59M
Issuance of capital stock 0.34M 0.00M 10.01M 1.84M 0.00M
Depreciation - 0.28M 0.01M 0.01M 0.01M
Other cashflows from investing activities - 0.33M 0.04M 0.00M 0.00M
Dividends paid - - - - 0.00M
Change to inventory - - - - 0.00M
Change to account receivables - - - - 0.00M
Sale purchase of stock - - - - 0.00M
Other cashflows from financing activities -0.19M 6.04M 0.61M 0.49M -2.05M
Change to netincome - -0.63M 0.47M 0.42M 0.72M
Capital expenditures 0.33M 0.43M 0.56M 0.50M 2.05M
Change receivables - - - - 0.00M
Cash flows other operating - - - - 0.00M
Exchange rate changes - - - - 0.00M
Cash and cash equivalents changes - - - - 0.00M
Free cash flow -0.33M -0.43M -0.56M -0.50M -2.05M

Peer Comparison*

Sector: Basic Materials Industry: Other Industrial Metals & Mining

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
BHPLF
BHP Group Limited
-
-%
34.27 19.59 15.20 3.72 3.95 7.44
BHP
BHP Group Limited
-1.32
1.93%
67.23 19.28 15.06 3.66 3.92 7.42
RTNTF
Rio Tinto Group
-
-%
91.08 15.69 13.70 3.05 4.44 12.05
RTPPF
Rio Tinto Group
-
-%
74.61 13.01 11.99 2.53 2.38 6.57

Profile*

Amur Minerals Corporation

CRISM Therapeutics Corporation focuses on drug delivery technology to improve the clinical performance of cancer drugs as treatments for solid tumors. Its lead product, ChemoSeed that can be implanted directly into a tumor or the resection margin following the removal of a tumor, ensuring effective therapeutic concentrations of chemotherapy drugs directly reach the tumor tissue. Its ChemoSeed used for treatment of gliomas, a brain tumor. The company was founded in 2016 and is based in Road Town, the British Virgin Islands.

Kingston Chambers, Road Town, British Virgin Islands

4

Name Title Year Born
Mr. Robin Jay Young CEO, Sec. & Exec. Director 1955
Mr. Ae Jack Swanson Chief Operating Officer 1938
Mr. Robin Jay Young CEO, Secretary & Executive Director 1955

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…